A multidisiplinary panel is presented with a highly allergic, extremely refractory patient with atopic dermatitis (AD). Her dermatologist wants to take the next step and start her on a biologic, but she is worried about the patient’s ocular history and dupilumab’s conjunctivitis risk. Find out what the experts have to say about this doctor’s dilemma.
Upon completion of this activity, participants should be better able to:
Assistant Professor, Clinical Dermatology and Pediatrics
Feinberg School of Medicine
Ann & Robert H. Lurie Children’s Hospital
Professor, Division of Allergy-Immunology
Department of Pediatrics
National Jewish Health and University of Colorado School of Medicine
Director, Clinical Research
Department of Dermatology
Oregon Health & Science University
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources